SCHEMBL16626669

SCHEMBL16626669

CNCc1cn(S(=O)(=O)c2cccc(F)c2)c2cc(Nc3ccc(C)cc3OC(F)(F)F)cnc12

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 8/20 0.36
DRD2 P14416 1/20 0.34
BRD4 O60885 2/20 0.33
SLC6A9 P48067 3/20 0.32
SLC6A4 P31645 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
EED O75530 1/20 0.31
HTR2A P28223 1/20 0.31
PTGDR Q13258 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
FGFR4 P22455 1/20 0.31
PPARG P37231 1/20 0.31
PPARD Q03181 1/20 0.31
PPARA Q07869 1/20 0.31
DHODH Q02127 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16619138 0.99 HTR6 (0.36) HTR6DRD2BRD4SLC6A9SLC6A4
SCHEMBL17971592 0.92 HTR6 (0.39) HTR6DRD2SLC6A4MEN1KMT2A
SCHEMBL16626660 0.88 HTR6 (0.40) HTR6DRD2BRD4EEDPTGDR
SCHEMBL16626777 0.88 HTR6 (0.40) HTR6DRD2SLC6A9HTR2AFGFR4
Hydrochloric Acid SCHEMBL16618870 0.87 HTR6 (0.41) HTR6DRD2SLC6A9HTR2AFGFR4
Hydrochloric Acid SCHEMBL16619040 0.87 HTR6 (0.39) HTR6DRD2BRD4EEDHTR2A
SCHEMBL17971591 0.84 HTR6 (0.46) HTR6DRD2MEN1KMT2AHTR2A
SCHEMBL16626666 0.82 HTR6 (0.39) HTR6DRD2BRD4SLC6A4
SCHEMBL19984281 0.81 SLC6A4 (0.33) SLC6A4
Hydrochloric Acid SCHEMBL16619579 0.81 HTR6 (0.38) HTR6DRD2BRD4SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI HTR6 166/4885DRD2 2007/4885BRD4 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.